A Phase 3 interventional study of Bendamustine and Rituximab in Mantle Cell Lymphoma, sponsored by Janssen Research & Development, LLC. Completed at 201 sites in 28 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-07-08.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing ibrutinib in Lymphoma, Mantle-Cell — 2 open to participants now, 16 under way, 2 of them phase 3. ibrutinib · Lymphoma, Mantle-Cell.
Among the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell, this one is the 3rd largest by enrollment, is one of 4 that started in 2013, is one of 6 in phase 3, and was the 7th registered.
1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.
Browse Lymphoma, Mantle-Cell studies →2 of the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell are open now, in 6 countries. Recruiting first, the newest first:
OHSU Knight Cancer Institute · Sites in United States
Ages 18+
Prof. Dr. M. Dreyling (co-chairman) · Sites in Denmark, Germany, Italy and 2 more countries
Ages 18–65
By country, each count listing its studies:
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 26 · Phase 3 6 · Phase 4 1
First in 2009; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 523 is above the median of 37 across 1,001 interventional studies indexed under Lymphoma, Mantle-Cell.
Median enrollment 39 across the 45 interventional studies. Of the 24 that completed or were terminated, 12 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 45 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson: none open now, 1 under way, 1 of them phase 3. Of 13 finished, 5 (38%) have results posted.
Among the 16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2013, is one of 3 in phase 3, and was the 4th registered.
Johnson & Johnson’s Lymphoma, Mantle-Cell studies by the year they started, since 2012.
6 of the studies testing ibrutinib in Lymphoma, Mantle-Cell that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT03710772M.D. Anderson Cancer CenterIbrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | 2027-03-22 |
| NCT03153202Joshua BrodyStudy to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | 2027-04 |
| NCT02427620M.D. Anderson Cancer CenterIbrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell, from their registry updates:
Among Johnson & Johnson’s 16 in Lymphoma, Mantle-Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of ibrutinib given in combination with bendamustine and rituximab in patients 65 years of age or older with newly diagnosed mantle cell lymphoma.
This is a randomized (individuals assigned to study treatment by chance), double blind (neither physician nor participant knows the treatment that the participant receives), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial)-controlled study to compare the efficacy and safety of ibrutinib given in combination with bendamustine and rituximab (BR) with BR alone in participants newly diagnosed with mantle cell lymphoma (MCL) who are 65 years of age or older. Approximately 520 participants will be randomly assigned in a 1:1 ratio and stratified by simplified Mantle Cell Lymphoma International Prognostic Index (MIPI) score (low risk [0-3] versus intermediate risk [4-5] versus high risk [6-11]). The treatment phase will extend from randomization until discontinuation of all study treatment or the clinical cutoff for the end of study. A cycle is defined as 28 days. All participants will receive open-label (identity of assigned study drug will be known) BR background therapy for a maximum of 6 cycles; participants with a complete response or partial response will continue to receive open-label background therapy with rituximab maintenance every second cycle for a maximum of 12 additional doses. In addition to the background therapy, all participants will receive blinded study drug (ibrutinib or placebo). Participants randomized to treatment Arm A will receive placebo capsules and participants randomized to treatment Arm B will receive ibrutinib capsules. Study drug will be administered daily and continuously until disease progression, unacceptable toxicity, or study end. Participants with stable disease after initial chemoimmunotherapy (BR+ibrutinib/placebo) should continue treatment with ibrutinib/placebo until disease progression, unacceptable toxicity, or study end. Participants with progressive disease must discontinue all study treatment. For participants who discontinue background therapy and do not have progressive disease, treatment with study drug will continue until disease progression or unacceptable toxicity or the clinical cutoff for the final analysis of progression-free survival (PFS). Participants receiving BR, rituximab, or ibrutinib at the clinical cutoff for the final analysis of PFS will continue open-label treatment until disease progression or unacceptable toxicity. Placebo will be stopped when the study is unblinded for the clinical cutoff for the final analysis of PFS. The posttreatment follow-up phase will begin once a participant discontinues bendamustine and rituximab and study drug. Participants who discontinue for reasons other than disease progression must continue to have disease evaluations as outlined in the protocol. Participants who discontinue due to disease progression will be followed for survival and subsequent anti-MCL therapy. The posttreatment follow-up phase will continue until death, lost to follow up, consent withdrawal, or study end, whichever occurs first. Four clinical cutoffs are planned. The first 3 clinical cutoffs will occur when approximately 134, 180, and 265 PFS events have been observed, respectively. The interim analyses and the final analysis of PFS will take place at these 3 clinical cutoffs, respectively; participant treatment assignment will be unblinded and placebo treatment will be stopped at the clinical cutoff for the final analysis of PFS. Treatment unblinding and stopping of placebo treatment could occur before the planned final analysis of PFS if recommended by the independent Data Monitoring Committee (DMC) after an interim analysis. The last cutoff will occur at the end of study, when 60% of the randomized participants have died or the Sponsor terminates the study, whichever comes first. Efficacy assessments will be conducted in accordance with the Revised Response Criteria for Malignant Lymphoma. Safety will be monitored throughout the study and summarized. Blood samples will be drawn for assessment of pharmacokinetic parameters. Blood and bone marrow will be collected for assessment of minimal residual disease and biomarker studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Bendamustine · Drug: Rituximab · Drug: Placebo
Drug: Bendamustine · Drug: Rituximab · Drug: Ibrutinib
90 mg/m2 administered intravenously on Days 1-2, Cycles 1-6
375 mg/m2 administered intravenously on Day 1, Cycles 1-6; if complete response or partial response is achieved, 375 mg/m2 is administered on Day 1 of every second cycle for a maximum of 12 additional doses
560 mg (4 x 140 mg capsules) administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end
4 capsules administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or the final analysis of progression-free survival
Progression-free Survival (PFS)
Progression-free survival (PFS) was defined as the interval between the date of randomization to the date of disease progression (PD) or relapse from complete response (CR) or death, whichever was first reported. Disease assessments were based on the 2007 Revised Response Criteria for Malignant Lymphoma. PD was defined as any new lesion or increase by 50 percent (%) of previously involved sites from nadir (PD criteria: Appearance of new nodal lesion 1.5 centimeters \[cm\] in any axis, 50% increase in sum of product of diameters \[SPD\] of greater than \[\>\] 1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis).
Time frame: Up to 97 months
Overall Survival
Overall survival was defined as the time from the date of randomization to the date of the participant's death. Kaplan-Meier estimate was used.
Time frame: From randomization (Day -3) up to 121 months
Complete Response Rate
Complete response (CR) rate was defined as the percentage of participants who achieve CR (based on investigator assessment) on or prior to the initiation of subsequent anticancer therapy. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if positron emission tomography (PET) negative; regression to normal size on computed tomography (CT); spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy.
Time frame: Up to 97 months
Time-to-Next Treatment
Time-to-next treatment was measured from the date of randomization to the start date of any anti-mantle cell lymphoma (anti-MCL) treatment subsequent to the study treatment.
Time frame: Up to 97 months
Percentage of Participants With Overall Response
Percentage of participants with overall response was defined as the portion of participants who achieved CR or PR. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy. Criteria for PR: greater than or equal to (\>=) 50% decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions.
Time frame: Up to 97 months
Minimal Residual Disease (MRD)-Negative Response Rate
Minimal residual disease negative rate was defined as the percentage of participants with a best overall response of CR with MRD-negative disease status (that is, \<5 mantle cell lymphoma \[MCL\] cell per 10,000 leukocytes for detection using the MRD assay), as assessed by flow cytometry of a bone marrow and/or peripheral blood sample.
Time frame: Up to 97 months
Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Questionnaire
Time to worsening in the Lymphoma subscale of the FACT-Lym, defined as the interval from the date of randomization to the start date of worsening of participant symptoms. Worsening was defined by a 5-point decrease from baseline, death, or a missing assessment due to being "too ill", whichever occurred first. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (higher the worse). Lymphoma subscale score was the total of reverse scores, ranged 0 to 60. Higher scores indicated a better quality of life.
Time frame: Up to 97 months
Duration of Response (DoR)
Duration of Response (DoR) was defined as the interval between the date of initial documentation of a response including PR and the date of first documented evidence of PD or death
Time frame: Up to 97 months
Duration of Complete Response (DoCR)
Duration of complete response (DoCR) was defined as the interval between the date of initial documentation of a CR and the date of first documented evidence of PD or death whichever occurs first.
Time frame: Up to 97 months
Time to Response
Time to response was defined as the interval between the date of randomization and the date of initial documentation of a response.
Time frame: Up to 97 months
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Number of participants with TEAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. Treatment-emergent adverse events were defined as adverse events with onset or worsening on or after date of first dose of study treatment up to and including 30 days after date of last dose of study medication, or the initiation of subsequent anticancer therapy, whichever is earlier.
Time frame: Placebo + BR (Treatment A): From first dose of study treatment (Day 1) up to 100.1 months; Ibrutinib + BR (Treatment B): From first dose of study treatment (Day 1) up to 117.2 months
Oral Plasma Clearance (CL/F) of Ibrutinib
CL/F was defined as apparent total systemic clearance of ibrutinib after extravascular administration. Cl/F of Ibrutinib was determined using population pharmacokinetics (PopPK modeling).
Time frame: Pre-dose on Day 2 of Cycles 1, 2 and 3; and 1, 2 and 4 hours post-dose on Day 2 of Cycles 1 and 2
Oral Volume of Distribution at Steady State of Ibrutinib
Oral volume of distribution at steady state of ibrutinib was determined using PopPK modeling.
Time frame: Pre-dose on Day 2 of Cycles 1, 2 and 3; and 1, 2 and 4 hours post-dose on Day 2 of Cycles 1 and 2
Area Under the Concentration Curve of Ibrutinib During 24 Hours After Dosing at Steady State
Area under the concentration curve of ibrutinib during 24 hours after dosing at steady state was determined using PopPK modeling.
Time frame: Pre-dose on Day 2 of Cycles 1, 2 and 3; and 1, 2 and 4 hours post-dose on Day 2 of Cycles 1 and 2
Minimum Observed Plasma Concentration of Ibrutinib
Minimum observed plasma concentration of ibrutinib was determined using PopPK modeling.
Time frame: Pre-dose on Day 2 of Cycles 1, 2 and 3; and 1, 2 and 4 hours post-dose on Day 2 of Cycles 1 and 2
Maximum Observed Plasma Concentration of Ibrutinib
Maximum observed plasma concentration of ibrutinib was determined using PopPK modeling.
Time frame: Pre-dose on Day 2 of Cycles 1, 2 and 3; and 1, 2 and 4 hours post-dose on Day 2 of Cycles 1 and 2
| Milestone | Placebo + Bendamustine and Rituximab (BR) (Treatment A) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) |
|---|---|---|
| Started | 262 | 261 |
| Safety analysis set (treated) | 260 | 259 |
| Completed | 129 | 119 |
| Not completed | 133 | 142 |
| Withdrew: Lost to follow-up | 12 | 7 |
| Withdrew: Withdrawal by subject | 32 | 48 |
| Withdrew: Sponsor decision | 89 | 87 |
Progression-free survival (PFS) was defined as the interval between the date of randomization to the date of disease progression (PD) or relapse from complete response (CR) or death, whichever was first reported. Disease assessments were based on the 2007 Revised Response Criteria for Malignant Lymphoma. PD was defined as any new lesion or increase by 50 percent (%) of previously involved sites from nadir (PD criteria: Appearance of new nodal lesion 1.5 centimeters \[cm\] in any axis, 50% increase in sum of product of diameters \[SPD\] of greater than \[\>\] 1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis).
| months | Placebo + Bendamustine and Rituximab (BR) (Treatment A) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) |
|---|---|---|
| Progression-free Survival (PFS) | 52.9 (43.7 to 71.0) | 80.6 (61.9 to NA) |
Overall survival was defined as the time from the date of randomization to the date of the participant's death. Kaplan-Meier estimate was used.
| months | Placebo + Bendamustine and Rituximab (BR) (Treatment A) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) |
|---|---|---|
| Overall Survival | 95.9 (86.1 to 115.3) | 104.3 (81.1 to NA) |
Complete response (CR) rate was defined as the percentage of participants who achieve CR (based on investigator assessment) on or prior to the initiation of subsequent anticancer therapy. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if positron emission tomography (PET) negative; regression to normal size on computed tomography (CT); spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy.
| percentage of participants | Placebo + Bendamustine and Rituximab (BR) (Treatment A) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) |
|---|---|---|
| Complete Response Rate | 57.6 | 65.5 |
Time-to-next treatment was measured from the date of randomization to the start date of any anti-mantle cell lymphoma (anti-MCL) treatment subsequent to the study treatment.
| months | Placebo + Bendamustine and Rituximab (BR) (Treatment A) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) |
|---|---|---|
| Time-to-Next Treatment | 92.0 (71.5 to NA) | NA (NA to NA) |
Percentage of participants with overall response was defined as the portion of participants who achieved CR or PR. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy. Criteria for PR: greater than or equal to (\>=) 50% decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions.
| percentage of participants | Placebo + Bendamustine and Rituximab (BR) (Treatment A) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) |
|---|---|---|
| Percentage of Participants With Overall Response | 88.5 | 89.7 |
Minimal residual disease negative rate was defined as the percentage of participants with a best overall response of CR with MRD-negative disease status (that is, \<5 mantle cell lymphoma \[MCL\] cell per 10,000 leukocytes for detection using the MRD assay), as assessed by flow cytometry of a bone marrow and/or peripheral blood sample.
| percentage of participants | Placebo + Bendamustine and Rituximab (BR) (Treatment A) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) |
|---|---|---|
| Minimal Residual Disease (MRD)-Negative Response Rate | 56.5 | 62.1 |
Time to worsening in the Lymphoma subscale of the FACT-Lym, defined as the interval from the date of randomization to the start date of worsening of participant symptoms. Worsening was defined by a 5-point decrease from baseline, death, or a missing assessment due to being "too ill", whichever occurred first. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (higher the worse). Lymphoma subscale score was the total of reverse scores, ranged 0 to 60. Higher scores indicated a better quality of life.
| months | Placebo + Bendamustine and Rituximab (BR) (Treatment A) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) |
|---|---|---|
| Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Questionnaire | 22.2 (9.3 to 34.0) | 17.4 (8.3 to 27.6) |
Duration of Response (DoR) was defined as the interval between the date of initial documentation of a response including PR and the date of first documented evidence of PD or death
| months | Placebo + Bendamustine and Rituximab (BR) (Treatment A) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) |
|---|---|---|
| Duration of Response (DoR) | 63.5 (47 to 76.9) | 81 (64.2 to NA) |
Duration of complete response (DoCR) was defined as the interval between the date of initial documentation of a CR and the date of first documented evidence of PD or death whichever occurs first.
| months | Placebo + Bendamustine and Rituximab (BR) (Treatment A) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) |
|---|---|---|
| Duration of Complete Response (DoCR) | 78.1 (65.6 to NA) | NA (81.7 to NA) |
Time to response was defined as the interval between the date of randomization and the date of initial documentation of a response.
| months | Placebo + Bendamustine and Rituximab (BR) (Treatment A) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) |
|---|---|---|
| Time to Response | 2.79 (1.9 to 11.2) | 2.79 (2.1 to 10.1) |
Number of participants with TEAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. Treatment-emergent adverse events were defined as adverse events with onset or worsening on or after date of first dose of study treatment up to and including 30 days after date of last dose of study medication, or the initiation of subsequent anticancer therapy, whichever is earlier.
| Participants | Placebo + Bendamustine and Rituximab (BR) (Treatment A) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 257 | 259 |
CL/F was defined as apparent total systemic clearance of ibrutinib after extravascular administration. Cl/F of Ibrutinib was determined using population pharmacokinetics (PopPK modeling).
| liter per hour (L/h) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) |
|---|---|
| Oral Plasma Clearance (CL/F) of Ibrutinib | 1123 ± 4.83 |
Oral volume of distribution at steady state of ibrutinib was determined using PopPK modeling.
| liter | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) |
|---|---|
| Oral Volume of Distribution at Steady State of Ibrutinib | 7286 ± 7.87 |
Area under the concentration curve of ibrutinib during 24 hours after dosing at steady state was determined using PopPK modeling.
| nanogram*hour per milliliter (ng*h/mL) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) |
|---|---|
| Area Under the Concentration Curve of Ibrutinib During 24 Hours After Dosing at Steady State | 425 ± 267 |
Minimum observed plasma concentration of ibrutinib was determined using PopPK modeling.
| nanograms per milliliter (ng/mL) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) |
|---|---|
| Minimum Observed Plasma Concentration of Ibrutinib | 3.90 ± 2.64 |
Maximum observed plasma concentration of ibrutinib was determined using PopPK modeling.
| ng/mL | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) |
|---|---|
| Maximum Observed Plasma Concentration of Ibrutinib | 74.5 ± 48.3 |
Collected over All-cause mortality: From randomization (Day -3) up to 121 months; SAEs and Non SAEs: Placebo + BR (Treatment A): From first dose of study treatment (Day 1) up to 100.1 months; Ibrutinib + BR (Treatment B): From first dose of study treatment (Day 1) up to 117.2 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + Bendamustine and Rituximab (BR) (Treatment A) | 129/262 (49.2%) | 157/260 (60.4%) | 255/260 (98.1%) |
| Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) | 120/261 (46%) | 201/259 (77.6%) | 256/259 (98.8%) |
| Event | Placebo + Bendamustine and Rituximab (BR) (Treatment A) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) |
|---|---|---|
| PneumoniaInfections and infestations | 35/260 | 58/259 |
| PyrexiaGeneral disorders | 14/260 | 19/259 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 9/260 | 16/259 |
| Atrial FibrillationCardiac disorders | 4/260 | 14/259 |
| SepsisInfections and infestations | 6/260 | 10/259 |
| CellulitisInfections and infestations | 3/260 | 9/259 |
| DiarrhoeaGastrointestinal disorders | 2/260 | 8/259 |
| Covid-19 PneumoniaInfections and infestations | 2/260 | 8/259 |
| Acute Kidney InjuryRenal and urinary disorders | 2/260 | 8/259 |
| BronchitisInfections and infestations | 4/260 | 7/259 |
| Event | Placebo + Bendamustine and Rituximab (BR) (Treatment A) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 96/260 | 119/259 |
| NeutropeniaBlood and lymphatic system disorders | 104/260 | 109/259 |
| NauseaGastrointestinal disorders | 107/260 | 109/259 |
| RashSkin and subcutaneous tissue disorders | 57/260 | 95/259 |
| PyrexiaGeneral disorders | 76/260 | 88/259 |
| CoughRespiratory, thoracic and mediastinal disorders | 85/260 | 78/259 |
| AnaemiaBlood and lymphatic system disorders | 60/260 | 83/259 |
| FatigueGeneral disorders | 77/260 | 79/259 |
| Upper Respiratory Tract InfectionInfections and infestations | 69/260 | 70/259 |
| ConstipationGastrointestinal disorders | 66/260 | 52/259 |
| Age, Continuous(years) | Placebo + Bendamustine and Rituximab (BR) (Treatment A) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) | Total |
|---|---|---|---|
| Mean | 71.7 ± 5.2 | 71.8 ± 5.04 | 71.7 ± 5.12 |
| Age, Customized(Participants) | Placebo + Bendamustine and Rituximab (BR) (Treatment A) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) | Total |
|---|---|---|---|
| 70 years and over | 154 | 162 | 316 |
| < 70 years | 108 | 99 | 207 |
| Sex: Female, Male(Participants) | Placebo + Bendamustine and Rituximab (BR) (Treatment A) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) | Total |
|---|---|---|---|
| Female | 76 | 83 | 159 |
| Male | 186 | 178 | 364 |
| Ethnicity (NIH/OMB)(Participants) | Placebo + Bendamustine and Rituximab (BR) (Treatment A) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) | Total |
|---|---|---|---|
| Hispanic or Latino | 17 | 18 | 35 |
| Not Hispanic or Latino | 234 | 232 | 466 |
| Unknown or Not Reported | 11 | 11 | 22 |
| Race/Ethnicity, Customized(Participants) | Placebo + Bendamustine and Rituximab (BR) (Treatment A) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 0 | 3 |
| Asian | 42 | 47 | 89 |
| Black or African American | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| White | 206 | 199 | 405 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 9 | 10 | 19 |
| Other | 0 | 2 | 2 |
| Region of Enrollment(Participants) | Placebo + Bendamustine and Rituximab (BR) (Treatment A) | Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) | Total |
|---|---|---|---|
| ARGENTINA | 0 | 4 | 4 |
| AUSTRALIA | 12 | 19 | 31 |
| BELGIUM | 10 | 5 | 15 |
| BRAZIL | 10 | 11 | 21 |
| CANADA | 7 | 4 | 11 |
| CHINA | 26 | 31 | 57 |
| CZECH REPUBLIC | 8 | 7 | 15 |
| FRANCE | 13 | 8 | 21 |
| GERMANY | 5 | 3 | 8 |
| GREECE | 3 | 4 | 7 |
| HUNGARY | 5 | 5 | 10 |
| IRELAND | 0 | 2 | 2 |
| ISRAEL | 9 | 5 | 14 |
| ITALY | 13 | 13 | 26 |
| JAPAN | 4 | 7 | 11 |
| MEXICO | 2 | 1 | 3 |
| NETHERLANDS | 3 | 5 | 8 |
| POLAND | 17 | 18 | 35 |
| RUSSIAN FEDERATION | 12 | 15 | 27 |
| SLOVAKIA | 2 | 1 | 3 |
| SOUTH KOREA | 6 | 6 | 12 |
| SPAIN | 7 | 13 | 20 |
| SWEDEN | 9 | 9 | 18 |
| TAIWAN | 4 | 2 | 6 |
| TURKEY | 6 | 8 | 14 |
| UKRAINE | 5 | 6 | 11 |
| UNITED KINGDOM | 16 | 14 | 30 |
| UNITED STATES | 48 | 35 | 83 |
Showing the first 100 of 201 sites across 28 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2013 to primary completion in Jun 2021, 97 months.
Results were first posted in Jul 2022, 1 year after primary completion.
Of 27 phase 3 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 97 months of starting (the median), counting those still running; a quarter within 68. This study's 97 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibrutinib
Janssen Research & Development, LLC →